The FDA assessed the protection and usefulness of atidarsagene autotemcel based on details from 37 young children who acquired atidarsagene autotemcel in two single-arm, open-label scientific trials and in an expanded obtain method.[7] Small children who acquired treatment with atidarsagene autotemcel were being as compared to untreated young child